Compugen Soars to Six-Year High on Cancer Treatment Bets

Compugen Ltd. surged to the highest level in six years on speculation the use of one of its products in cancer treatment research will boost revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.